专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090191177A1 Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 审中-公开
标题翻译：对映异构体纯（ - ）2- [1-（7-甲基-2-（吗啉-4-基）-4-氧代-4H-吡啶并[1,2-A]嘧啶-9-基）乙基氨基]苯甲酸，其用于医学治疗，以及包含其中的药物组合物 - 026
公开(公告)号：US20090191177A1
公开(公告)日：2009-07-30
申请号：US12359323
申请日：2009-01-25
申请人： Ola Fjellstrom , David Gustafsson , Jan A. Lindberg , Shaun Jackson
发明人： Ola Fjellstrom , David Gustafsson , Jan A. Lindberg , Shaun Jackson
IPC分类号： C07D471/04 , A61K31/5355 , A61K31/727 , A61K38/45 , A61P7/00 , A61P9/00
CPC分类号： C07D471/04
摘要： The present invention relates to enantiomerically pure (−) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase β and use of the selective inhibitor in e.g. anti-thrombotic therapy.
摘要翻译：本发明涉及对映体纯的（ - ）2- [1-（7-甲基-2-（吗啉-4-基）-4-氧代-4H-吡啶并[1,2-a]嘧啶-9-基）乙基氨基]苯甲酸或其药学上可接受的盐，其为固体状态，其在医学治疗中的应用，包含其的药物组合物，其用于制备用于预防或治疗疾病的方法的药物及其用途在预防或治疗疾病的方法中。本发明涉及磷酸肌醇（PI）3-激酶β的选择性抑制剂和选择性抑制剂的用途。抗血栓治疗。

2. 发明授权

US06977255B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US06977255B2
公开(公告)日：2005-12-20
申请号：US10181485
申请日：2001-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yap , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yap , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K9/02 , A61K9/08 , A61K9/12 , A61K9/20 , A61K9/48 , A61K31/5377 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04 , A61K31/352
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 包括诸如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌等癌症的肿瘤，以及与无序白细胞功能相关的疾病，例如自身免疫性和炎性疾病。

3. 发明申请

US20080206312A1 Therapeutic Morpholino-Substituted Compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US20080206312A1
公开(公告)日：2008-08-28
申请号：US12019061
申请日：2008-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , C07D413/04 , A61K9/12 , A61K47/06 , A61P9/00 , A61P11/00 , A61P35/04 , A61P7/00
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

4. 发明申请

US20050085471A1 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US20050085471A1
公开(公告)日：2005-04-21
申请号：US10961062
申请日：2004-10-12
申请人： Alan Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K9/02 , A61K9/08 , A61K9/12 , A61K9/20 , A61K9/48 , A61K31/5377 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04 , C07D413/04
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

5. 发明申请

US20060289444A1 In-case computer charging system 审中-公开
标题翻译：机箱电脑充电系统
公开(公告)号：US20060289444A1
公开(公告)日：2006-12-28
申请号：US11441586
申请日：2006-05-26
申请人： Shaun Jackson , Mark Zadvinskis
发明人： Shaun Jackson , Mark Zadvinskis
IPC分类号： F27D11/00
CPC分类号： B64D15/12 , B32B5/024 , B32B5/12 , B32B5/26 , B32B2250/03 , B32B2250/20 , B32B2250/40 , B32B2255/02 , B32B2255/205 , B32B2260/023 , B32B2260/046 , B32B2262/101 , B32B2262/106 , B32B2307/54 , B32B2603/00 , G06F1/1628 , G06F1/1632 , H05B3/347 , H05B2203/007 , H05B2203/014 , H05B2203/017
摘要： A case configured to enclose a portable electronic device includes a plurality of externally accessible electrical contacts, enabling electrical current to flow to or from the device while enclosed in the case. The invention is applicable to all types of portable devices, including laptop, notebook and palm-top computers, as well as telecommunications devices, video players and music players. Typically the electrical contacts allow a battery in the case or in the device to be recharged while device is enclosed. An adaptor cable may be provided between the device and the electrical contacts so that the same or similar case may be used with different model devices from different manufacturers. For greater ‘universality,’ a voltage-changing adaptor cable may be provided within the case between the device and the electrical contacts. The system may further include a docking bay to receive the case, the docking bay having a set of electrical contacts configured to electrically engage with the contacts on the case. Such a docking bay may take the form of a charging stand, a cart with one or more slots or compartments, or a locker with a door and a storage compartment.
摘要翻译：被配置为封闭便携式电子设备的壳体包括多个可外部访问的电触头，使得电流能够流入或流出设备，同时封闭在外壳中。本发明适用于所有类型的便携式设备，包括笔记本电脑，笔记本电脑和掌上电脑以及电信设备，视频播放器和音乐播放器。通常，电触点允许在封装设备的情况下或在设备中的电池被充电。可以在设备和电触点之间提供适配器电缆，使得可以使用与不同制造商的不同型号的设备相同或相似的情况。为了获得更大的“通用性”，可以在设备和电气触点之间的壳体内提供电压改变的适配器电缆。该系统还可以包括用于容纳壳体的对接舱，该对接舱具有一组电触点，其被配置为与壳体上的触点电接合。这样的对接托架可以采取充电架，具有一个或多个槽或隔间的推车，或具有门和储物室的储物柜的形式。

6. 发明申请

US20110190270A1 METHODS OF TREATING THROMBOEMBOLIC DISORDERS 审中-公开
标题翻译：治疗血栓性疾病的方法
公开(公告)号：US20110190270A1
公开(公告)日：2011-08-04
申请号：US12865375
申请日：2009-01-30
申请人： Shaun Jackson , Simone Schoenwaelder , Akiko Ono
发明人： Shaun Jackson , Simone Schoenwaelder , Akiko Ono
IPC分类号： A61K31/551 , A61K31/44 , A61K31/437 , A61P7/02
CPC分类号： A61K31/4409 , A61K31/4725 , A61K31/4745 , A61K31/551 , A61K31/727 , A61K38/49 , A61K45/06 , A61K2300/00
摘要： The field of the invention relates to methods for dissolving a thrombus using inhibitors of platelet contractility. More particularly, the present invention relates to the use of an inhibitor of platelet contractility in combination with one or more thrombolytic agents and optionally one or more anticoagulants for inhibiting platelet contraction and consolidation in the developing thrombus.
摘要翻译：本发明的领域涉及使用血小板收缩性抑制剂溶解血栓的方法。更具体地说，本发明涉及血小板收缩抑制剂与一种或多种血栓溶解剂和任选的一种或多种抗凝血剂联合用于抑制发展中血栓中血小板收缩和巩固的用途。

7. 发明授权

US07572791B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US07572791B2
公开(公告)日：2009-08-11
申请号：US12019061
申请日：2008-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5375 , C07D413/02
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

8. 发明申请

US20080312233A1 Therapeutic Morpholino-Substituted Compounds 审中-公开
公开(公告)号：US20080312233A1
公开(公告)日：2008-12-18
申请号：US12115563
申请日：2008-05-06
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , A61P11/00 , A61P9/00
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

9. 发明授权

US07405211B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US07405211B2
公开(公告)日：2008-07-29
申请号：US10961062
申请日：2004-10-12
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , C07D413/04
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

10. 发明申请

US20060276470A1 Inhibition of phsphoinostide 3-dinase beta 失效
标题翻译：磷酸霍乱碱3-二肽酶β的抑制
公开(公告)号：US20060276470A1
公开(公告)日：2006-12-07
申请号：US10522777
申请日：2003-08-18
申请人： Shaun Jackson , Alan Robertson , Vijaya Kenche , Philip Thompson , Hishani Prabaharan
发明人： Shaun Jackson , Alan Robertson , Vijaya Kenche , Philip Thompson , Hishani Prabaharan
IPC分类号： A61K31/5377 , C07D487/04
CPC分类号： C07D401/04 , A61K31/4709 , A61K31/519 , A61K31/5365 , A61K31/5375 , A61K31/5377 , C07D405/04 , C07D471/04
摘要： The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.
摘要翻译：本发明涉及磷酸肌醇（PI）3-激酶β的选择性抑制剂，选择性抑制剂在抗血栓形成治疗中的应用，以及通过检测PI 3的选择性抑制活性来筛选可用于新的抗血栓形成治疗的化合物的方法 - 化合物的激酶β。本发明还涉及作为PI3-激酶抑制剂的新化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式